The effect of growth hormone on granulosa cell function during in-vitro fertilization.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.

Growth hormone or placebo were added in a prospective, randomized and double-blind manner to an existing IVF stimulation protocol.

Follicular stimulation with HMG was started after pituitary down-regulation.

Who Took Part

The study group was 14 patients.

The age groups tagged for this paper are adults, women only.

Forty-two normal ovulatory women (< or = 38 years old) with mechanical factor infertility and normal male factor were included in the study.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

Gonadotrophin-releasing hormone agonist (GnRHa) was given from day 21 of the previous cycle until human chorionic gonadotrophin (HCG) administration.

What Was Measured

The subject headings attached to it are Fertilization in Vitro, Granulosa Cells, Growth Hormone, Menotropins and Triptorelin Pamoate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and HMG (Human Menopausal Gonadotropin) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.